BMS-962212 / BMS - LARVOL DELTA

Evolution of potent factor Xa and factor XIa inhibitors, leading to the design and synthesis of apixaban (Eliquis®) and BMS-962212 (ACS-Fall 2022) - "Recently, coagulation Factor XIa has emerged as a promising target with genetic, epidemiologic and preclinical evidence supporting the potential for highly effective antithrombotic efficacy with minimal effects on hemostasis. The design and synthesis of compounds targeting key blood coagulation enzymes, Factor Xa and Factor XIa will be discussed, highlighted by the discovery of apixaban (Eliquis®) and BMS-962212, a parenteral first in class Factor XIa inhibitor."

Atrial Fibrillation • Cardiovascular • Venous Thromboembolism

The effect of water on the large-scale supercritical fluid chromatography purification of two factor XIa active pharmaceutical ingredients. (PubMed, J Chromatogr A) - "BMS-962212, a parenteral Factor XIa inhibitor, was scaled-up for toxicity studies...A throughput of 2 g/h was achieved, and >80 g of the crude API was purified. The same strategy was applied to another Factor XIa API (compound A) and its penultimate."

Journal